Oragenics Announces Closing of $6.5 Million Registered Direct Offering

TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the closing of its previously announced registered direct offering of 14,444,444 shares of common stock at a purchase price of $0.45 per share. A.G.P./Alliance … [Read more…]

Shift4 Payments: As Merchants Persevere Throughout the Fall, Transaction Volumes Show Continuing Impact of COVID-19

Despite an October in which transaction volumes exceeded seasonal expectations, November transaction volumes reveal the impact of the ongoing pandemic ALLENTOWN, Pa. & LAS VEGAS–(BUSINESS WIRE)–Shift4 Payments (NYSE: FOUR), the leader in integrated payment processing solutions, has revealed that the month-over-month change in U.S. merchant transaction volumes from October to November dipped more than in … [Read more…]

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The second-generation human adenovirus vector hAd5, which delivers both outer spike (S) and inner nucleocapsid (N) antigens, induced T cells and antibodies … [Read more…]

Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate

Interim durability data from NIH-led Phase 1 study of mRNA-1273 published as letter to the editor in NEJM; at day 119, 3 months post-second 100 μg dose, binding and neutralizing antibody titers remain high in all participants; results consistent across all age groups (18-55, 56-70 and 71+) Company reaffirms expectation to have 20 million doses … [Read more…]

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

UK government has now secured 7 million doses of mRNA-1273 Agreement reflects Moderna’s commitment to make its vaccine available in multiple countries CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the … [Read more…]

Global Pharmaceutical Packaging Equipment Market 2020-2027: Unprecedented Global Push to Expedite COVID-19 Vaccine Development to Spur Demand – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Packaging Equipment – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. With the World Awaiting Vaccine Supply for 7.5 Billion People, the Drug Packaging Market Remains Optimistic With a 13.2% Spike in Revenues The global market for Pharmaceutical Packaging Equipment is expected to witness a 13.2% spurt in … [Read more…]

Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

– Completed $44.9M IPO in October –– Identified COVID 19 Neutralizing antibodies –– Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense – EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop … [Read more…]

Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)

Acceleration in rate of COVID-19 disease across trial sites; Company expects more than 53 cases will be submitted to Data Safety Monitoring Board for the first interim analysis CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today … [Read more…]

BIOQUAL Announces Publication of an Investigational COVID-19 Vaccine Candidate That Prevents Severe Clinical Disease in Animals

ROCKVILLE, Md.–(BUSINESS WIRE)–A major objective of a COVID-19 vaccine is to prevent severe disease onset in SARS-CoV-2 infected people. Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that … [Read more…]

Avacta to Launch SARS-CoV-2 ELISA Laboratory Test

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus CAMBRIDGE & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support … [Read more…]